Radiation Therapy for Prostate Cancer with Elekta
Prostate cancer is a huge global issue, with over 1.4 million diagnoses every year—set to reach over 2 million in the next 10 years.1
Elekta places our clinical partners at the forefront of prostate cancer radiotherapy evolution
Radiation therapy, including brachytherapy, is a vital option in prostate cancer treatment for optimal patient outcomes. Radiation therapy has curative intent for early-stage disease and aims to shrink cancer or relieve symptoms in more advanced stages.
The drive to improve prostate treatment efficiency whilst improving patient experience in radiotherapy including quality of life for patients has led to increased hypofractionation, with demand continuing to drive strong growth in stereotactic body radiation therapy (SBRT). This has been enabled by technology advances and clinical evidence generation and this continues to evolve. SBRT is widely used for localized low/intermediate risk disease, but promising data and technology evolution mean more national guidelines are endorsing its use for high-risk disease as well. The use of SBRT is also increasing in the metastatic settings, including oligometastatic prostate cancer.
Elekta offers comprehensive solutions to suit any clinic serving prostate cancer patients—offering the best options with unique capabilities across the spectrum of the disease.
Elekta's solutions are truly comprehensive
Offerings that allow clinicians to maximize outcomes across the spectrum of the disease.
low-risk
intermediate-risk
high-risk
advanced
metastases
Metastatic
Brachytherapy
Submillimeter accuracy often used in combination with external beam radiation therapy.
Unity MR-Linac
Visualization and adaptation that takes prostate SBRT towards ultra-hypofractionation and beyond.
CT-Linacs
Comprehensive solutions can treat patients at any stage and deliver SBRT in < 90 seconds.
Elekta's radiation therapy machines for Prostate Cancer
Elekta CT-Linacs for Prostate Cancer
With the ability to deliver short-course SBRT in 90 seconds or less, our range of linear accelerators provides patients with prostate cancer the advantage of receiving highly-precise, personalized external beam radiation therapy at any stage. Elekta Evo now adds an online adaptive CT-Linac solution for prostate cancer treatments.
Elekta CT-Linacs for prostate treatment
Elekta Versa HD Elekta Harmony Elekta Evo**Elekta Evo is CE marked and pending U.S. FDA 510(k) clearance with limited global availability.
Elekta MR-Linac for Prostate Cancer
Elekta Unity, MR-guided radiation therapy offers the most advanced technology to expand prostate SBRT to more patients. The unique capability to see the prostate and surrounding organs in supreme detail as you treat, means immediate response to motion, and change in every patient, for every treatment. This certainty is enabling adaptive radiation therapy with reductions in margins and is moving clinicians towards a paradigm shift in prostate ultra-hypofractionation, whilst preserving quality of life and function.
Elekta MR-Linac for prostate treatment
Elekta Unity
Elekta Brachytherapy for Prostate Cancer
It's most often prescribed as a ‘boost’ following external beam radiation therapy for patients with intermediate or high-risk disease. A highly targeted post-external beam radiation therapy boost of High Dose Rate (HDR) brachytherapy has been shown to result in a higher prostate cancer control rate than EBRT alone2-3, earning the technique an important place in the treatment of eligible intermediate and high-risk patients.
Elekta Brachytherapy leads the market, with indispensable solutions, providing seamless and fast workflows for these key treatments.
Brachytherapy for prostate treatment
References
- Cancer Tomorrow | IARC - https://gco.iarc.who.int Data version: Globocan 2022 (version 1.1) - 08.02.2024
- Ishiyama H, Kamitani N, Kawamura H, et al. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Brachytherapy 2017;16:503-10. [Crossref] [PubMed]
- Spratt DE, Zumsteg ZS, Ghadjar P, et al. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 2014;114:360-7. [PubMed]